• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Inspire medical systems upsizes IPO

biospectrumasiaMay 07, 2018

Tag: obstructive sleep apnea , Inspire Medical Systems , IPO

Inspire Medical Systems, which sells an implanted device for treating obstructive sleep apnea, raised $108 million by offering 6.75 million shares at $16, the high end of the range of $14 to $16. It had previously filed to offer 5.0 million shares at the same range. Inspire Medical Systems plans to list on the NYSE under the symbol INSP. BofA Merrill Lynch and Goldman Sachs acted as lead managers on the deal.

The debut date has not been announced yet.

Register as Visitor to CPhI China 2018!

Previous:New study gives hope to fight minimal tumors

Next:Daily aspirin linked to higher risk in men

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Inspire medical systems upsizes IPO | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Tripossium Glycyrrhiznate

Tripossium Glycyrrhiznate
Liposomal Guaiazulene

Liposomal Guaiazulene
Alpha Lipoic Acid

Alpha Lipoic Acid
Alpha Lipoic Acid Powder

Alpha Lipoic Acid Powder
Alpha Lipoic Acid / ALA 1077-28-7

Alpha Lipoic Acid / ALA 1077-28-7
Buffering Agent Tripotassium Phosphate (TKP) K3po4 with High Purity

Buffering Agent Tripotassium Phosphate (TKP) K3po4 with High Purity
Potassium Tripolyphosphate(KTPP)

Potassium Tripolyphosphate(KTPP)
TFF ultrafiltration / liposome ultrafiltration/LDS-L1 TANGENTIAL FLOW FILTRATION

TFF ultrafiltration / liposome ultrafiltration/LDS-L1 TANGENTIAL FLOW FILTRATION
Dipotassium Glycyrrhizinate

Dipotassium Glycyrrhizinate
LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / liposome ultrafiltration

LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / liposome ultrafiltration

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service